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Abstract 
"
Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent cancer worldwide, 
and HPV-16 is found in ~60% of cases. The oncogenic nature of HPV is primarily attributed to 
proteins E6 and E7which are up regulated in infected host cells. T cells have been detected in the 
tumour of patients and correlate with improved prognosis. As a step towards the analysis of HPV-
specific T cell responses in tumours of HNSCC patients we have worked towards optimising a 
cultured IFN-γ ELISPOT assay using Epstein Barr virus (EBV) peptide CLG as a model.  Optimal 
culture conditions and blocking reagents for use in the IFN-γ ELISPOT assay were investigated. 
We found lowest backgrounds when cells were cultured in serum-free AIM-V medium, and 
ELISPOT plates are blocked with 10% albumin from bovine serum (BSA)or 10%autologous 
plasma. We have demonstrated that culturing PBMCs with peptide prior to performing the 
ELISPOT assay significantly amplifies the antigen-specific T cell response detected compared to 
standard ELISPOT assays performed overnight on PBMCs ex vivo. Future work must now focus 
on the translation of this optimised cultured ELISPOT assay for the detection of HPV-specific T 
cells in the tumours and peripheral blood of patients with HPV+ HNSCC. 
 
"  
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Introduction 
 
Human papillomaviruses (HPV) in head and neck cancer 
 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent cancer worldwide, 
with an estimated 500,000 new cases each year[42]. A number of genetic influences have been 
linked to the development of HNSCC and major environmental risk factors include smoking and 
alcohol consumption [43].   HPV is the most common sexually transmitted disease and infection 
with this virus has been causally linked to invasive cervical carcinoma [44, 45]. More  recently, 
infection with high risk HPV-subtypes, and in particular HPV-16 and HPV-18,  have been 
associated with HNSCC independent of other risk factors [44, 46, 47]. HPV-16 is estimated to be 
found in ~60% of oropharyngeal SCCs[48, 49]. HPV-positive HNSCCs are considered to be a 
distinct subset of HNSCC with improved prognosis and better response to treatment.[50] Evidence 
that higher viral loads in tonsil cancer correlates to better disease outcomes, suggests that the host 
is able to mount an active immune response to HPV, however this has not been thoroughly 
investigated.[51]  
 
HPV-16 preferentially invades cells in epithelial surfaces and integrates its genome into the host 
nucleus [48]. The oncogenic nature of high risk HPV is primarily attributed to proteins E6 and 
E7which are up regulated in infected host cells[52]. E6 inhibits and degrades tumour suppressor 
p53 in infected cells, while E7 binds to retinoblastoma suppressor pRb and causes the cell to enter 
the S-phase of the cell cycle [53].Together these oncogenic proteins induce transformation and 
immortalisation of infected cells[54, 55]. 
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Since the successful development of a vaccine for HPV-induced invasive cervical carcinoma, 
attention has turned to the investigation of immune responses to HPV in HNSCC. It has been 
shown that HPV oncogenic proteins E6 and E7 are preferentially and exclusively expressed in 
HPV infected tumour cells and HPV specific antibodies have been described in oral rinses and 
sera from HNSCC patients[56] [57]. T cells have been identified infiltrating tumours, and higher 
titres have been associated with improved prognosis although these responses are not well 
examined [58, 59]. The identification of active immune responses in HNSCC patients highlights the 
potential for the development of novel prophylactic vaccines, and suggests that there may be 
scope for the creation of immunotherapies for the treatment of this prevalent cancer. 
 
Detection of T cell responses – the ELISPOT assay 
 
Several methods for the detection of T cell responses are commonly used each method with its 
advantages and pitfalls. MHC-tetramer staining is a powerful tool for the identification of antigen 
specific T cells in a mixed population and works by binding of the T cell receptor (TCR) to known 
peptide-MHC complexes[60]. This method involves the production of multimeric MHC-peptide 
complexes labelled with streptavidin-biotin. Using four MHC molecules coupled together increases 
TCR-MHC binding avidity and therefore stable binding of the tetrameric structure to the cell surface 
and detection by flow cytometry methods[61]. However, tetramers alone cannot indicate the 
functional nature of the identified T cells, but must be used in conjunction with other flow cytometry 
protocols. Furthermore, developing new MHC tetramers is very expensive and most importantly 
requires prior knowledge of the target peptide antigen. Although peptide-specific responses have 
been described in cervical cancer, the epitopes of E6 and E7 which may be significant in HNSSC 
have not been thoroughly investigated[62]. For the purpose of this investigation, peptide pools 
spanning the full lengths of E7 and E7 will be used to ensure novel responses are not overlooked. 
MHC tetramer staining is therefore not a suitable method for use in this project [63].  
42"
"
 
Multi-parameter flow cytometry is a valuable method for revealing the cytokine profile and 
functional characteristics of antigen specific T cells by the simultaneous staining for intracellular 
cytokines and membrane bound cellular markers using fluorescently labelled monoclonal 
antibodies [63]. Cells are stimulated with peptide prior to staining to ensure detection of antigen 
specific responses above the level of spontaneous cytokine production [64]. Flow cytometry is 
expensive, and while it can be used to can quantify intracellular levels of cytokines such as IFN-γ, 
these levels may not correspond to the quantity of cytokine secreted by the cells. Furthermore 
cytokine flow cytometry is reported to be less sensitive for detecting low level responses compared 
to the enzyme-linked immunospot (ELISPOT) assay[65].  
 
ELISPOT assays are relatively inexpensive and enable quantification and functionality of T cells to 
be assessed simultaneously directly after antigen stimulation. A number of different ELISPOT 
assays have been developed to assess the production of various cytokines by immune cells, but 
the IFN-γ ELISPOT is the most commonly used. The ELISPOT assay is a plate ‘sandwich’ assay 
during which live cells are cultured overnight with antigenic stimulation. Cytokines produced and 
secreted by activated cells during the assay are captured by primary cytokine-specific monoclonal 
antibodies which are used to coat the wells of the ELISPOT plate. A secondary, biotinylated 
monoclonal antibody is added and spots are developed by incubation with conjugated streptavidin 
and the addition of a chromogen substrate. [66] Each spot represents a single cell producing the 
cytokine of interest and spot size correlates to the amount of cytokine produced by that cell. In 
contrast to MHC tetramer staining, the ELISPOT assay is not restricted to distinct peptides as 
peptide pools or target cells expressing whole proteins may be used for in vitro stimulation of the T 
cells applied to the assay. ELISPOT assays are regularly used in vaccine trials, but have also been 
utilized for the investigation of viral immunity and for the diagnosis of bacterial infection [67] [63-65] 
[68, 69].  IFN-γ ELISPOT assays have been successfully employed for the detection of HPV-
specific T cell responses in cervical cancer studies, suggesting they may be suitable for use during 
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this project [70]. Cultured ELISPOT assays, in which PBMCs are cultured for several days prior to 
the assay, have also been described for detection of low frequency T cell responses.[71-73] 
Culturing cells with the antigen of interest allows for preferential amplification of peptide specific T 
cells and subsequent detection of a T cell response which may have been overlooked by standard 
ELISPOT analysis.  Amplification of T cell responses may be maximised by supplementation with 
IL-2, which causes T cell proliferation [74].Since HPV-specific T cell responses in HNSCC are 
expected to be relatively low frequency and the functional capacity of the cells is not well 
investigated, cultured ELISPOT assays may be the best method for their detection[58, 63, 75]. 
 
Numerous protocols for standard and cultured ELISPOT assays have been described and the 
importance of optimising and harmonising the assay is emphasised in the literature [67, 76]. Small 
protocol changes have been reported to dramatically affect ELISPOT sensitivity.  When 
considering the development of an assay involving clinical samples it should be noted that delays 
in processing blood samples may have dramatic effects on the sensitivity of the standard ELISPOT 
assay [77]. The culture medium used during the assay is an important variable that is often 
overlooked.  RPMI 1640 supplemented with whole serum is frequently used for cell culture. 
However, some recommend serum-free medium such as AIM-V for cultured ELISPOT assays as it 
avoids the introduction of foreign antigens which may be present in fetal bovine serum or human 
serum and  which may induce T cell activation[67, 78]. It is clear that when designing an ELISPOT 
protocol (ex vivo or cultured), variables at every stage of the assay should be carefully considered, 
most notably; culture medium, length of culture, cell numbers applied per well and plate 
preparation and blocking reagents [67].  
 
"
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Aims  
1. To optimise the cultured ELISPOT assay for the detection of low frequency T cell 
responses to defined EBV peptide epitopes. 
2. To compare the magnitude of antigen specific responses detected using ex vivo and 
cultured ELISPOT assays. 
3. To investigate HPV-specific T cell responses in the tumours and peripheral blood of 
patients with HNSCC. 
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Materials and Methods 
 
Epstein Barr virus as a model for HPV responses 
 
Patients with HNSCC are expected to have low frequency T cell responses to HPV-peptides. For 
the optimisation of the ELISPOT assays healthy donors known to have weak responses to the EBV 
peptide CLG were selected and tested[79].  CLG and IED are HLA A2- and B40- restricted 
epitopes respectively from the latent membrane protein 2 (LMP2) of EBV. 
 
Healthy donors and cone cells  
"
In accordance with ethical approval and following informed written consent, blood samples were 
taken from 5 healthy donors (3 men and 2 women) known to be HLA-A2 positive, from the Cancer 
Sciences faculty of the University of Birmingham. These samples were used for the detection of 
weak T cell responses to EBV peptide CLG. 
 
Frozen aliquots of peripheral blood mononuclear cells (PBMC) derived from leukoreduction system 
chambers obtained from NBS platelet donors (cone cells) from 8 donors were selected at random 
and used for the detection of T cell responses to HPV-16 proteins E6 and E7. Donor age and 
gender of these samples were unknown. 
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Isolation of PBMC 
"
Heparin was added to the syringe prior to blood collection to avoid clotting. The blood sample was 
diluted in an equal volume of RPMI 1640. 30ml diluted blood was then carefully layered on to 15ml 
Lymphoprep (Axis-Shield, Norway). The tubes were then centrifuged at 800g for 30 minutes. The 
plasma layer was carefully removed and stored for use in subsequent experiments.  PBMCs were 
aspirated from the layer at the interface between the blood and the Lymphoprep. The isolated 
PBMCs were washed 3 times RPMI 1640: at 700g for 10 minutes, at 600g for 5 minutes and at 
400g for 5 minutes . Finally, the PBMCs were counted using a haemocytometer.  
 
PBMCs not being immediately used in ELISPOT assays were stored in freezing medium (10% 
Dimethyl sulfoxide (DMSO) and 90% FCS)at -80oC for up to 3 days and if still unused, were 
transferred to -180 C until ELISPOT analyses could be carried out.   
 
Peptides 
"
EBV peptides CLG and IED(Alta Bioscience) stock was kept at -20oC at 14mg/ml and was diluted 
to 40µg/ml for use in the ELISPOT assays.  Pepmixes contained peptide fragments of 15 amino 
acids which overlapped by 11 amino acids and covered the full length of the proteins HPV-16 E6 
(37 peptides) and E7 (22peptides) and human actin (92 peptides) (JPT Peptide Technologies, 
Germany). The pepmixes were diluted in DMSO to a final concentration for individual peptides of 
0.2µg/µl and stored at -20oC in 10µl aliquots to avoid multiple freeze thawing.  
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ELISPOT assays 
"
Where possible, PBMCs from healthy donors were used on the day of isolation. However, if this 
was not possible the PBMCs were stored at -80 C until use. Frozen healthy donor PBMCs and 
cone cells were thawed, washed with RPMI 1640 and rested overnight in RPMI 1640 with 10% 
fetal bovine serum (FBS), 1% GPS (penicillin, streptomycin and L-glutamine) in a 37oC incubator 
before use. ‘Ex vivo’ and cultured ELISPOT assays were carried out in parallel.  
 
PBMCs from healthy donors were tested for T cell responses to EBV peptide CLG. First, suitable 
culture medium and culture conditions were investigated. 3x106 PBMCs were cultured for 6 days 
(on the advicee of a faculty member at the Institute of Cancer Sciences) in a 24 well tissue culture 
plate in 2ml of AIM-V, Opti-Mem, RPMI 1640 +10% FBS or RPMI + 10% autologous plasma. 10µg 
CLG was added to each culture. The cells were cultured with or without 20 IU/ml IL-2. Half of the 
cells had the IL-2 washed off on day 5 and were rested overnight in their respective culture 
medium. 
 
Cone cell PBMCs were tested for T cell responses to HPV-16 proteins E6 and E7. 1.5x106 cells 
were cultured for 6 days in a 48 well tissue culture plate. On day 1, 0.2ug E6 and 0.2 µg E7 were 
added to the cells in 0.5ml AIM-v medium. On day 2 a further 0.5ml AIM-V was added and the cells 
were incubated at 37 C until use. On day 6 cultured cells were washed 3 times in RPMI 1640 the 
pellet was resuspended in the AIM-V at a concentration of 1x106 cells/ml for the ELISPOT assay. 
 
ELISPOT kit for human IFN-γ (Mabtech, Sweden) was used. First, MultiScreen 96- well plates 
(Millipore) were prewetted with 70% ethanol and washed twice with sterile filtered PBS. 50µl of the 
IFN-γ capture antibody was added to the plates at 7.5µg/ml and the plates were left at room 
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temperature for 4 hours. The plates were then washed 4 times with RPMI 1640 and blocked for 1 
hour at room temperature with 100µl of 10% bovine serum albumin (BSA) (Sigma-Aldrich), 
10%FBS or 10% autologous plasma. For ELISPOT assays detecting T cell responses to EBV 
peptide CLG, 1x105 PBMCs were added to 3 replicate wells along with 4µg CLG (dissolved in 
DMSO), an equivalent concentration of DMSO solvent (negative control) or 8µg PHA (positive 
control) , to a total volume of 100µl/well. For ELISPOT assays detecting T cell responses to HPV 
peptides, 1x105 PBMCs were added to 3 replicate wells along with 0.1µg E6 + 0.1µg E7, 8µg PHA 
(positive control) or an equivalent dilution of DMSO (negative control) or 0.1µg human actin 
(negative control) to a total volume of 110µl/well. 
 
The ELISPOTs were incubated for 18 hours at 37 C and then washed 4 times with 0.05% Tween 
20 solution in PBS. 50µl of the detection antibody was then added at 1µg/ml and the plates were 
incubated at room temperature for 3 hours. The plates were again washed 4 times with 0.05% 
Tween 20 solution in PBS. 50µl Streptavidin-Alkaline Phosphatase was added at 1µg/ml and the 
plate was incubated at room temperature for 1.5 hours. The wells and the undersides of the plates 
were washed 8 times with 0.05% Tween 20 solution in PBS, and 4 times with PBS and the 
chromogen substrate was added at 100µl/well. After 1 hour the plates were rinsed several times 
under the tap and left overnight to dry. Spots were counted using an ELISPOT reader system 
(Autoimmun Diagnostika GMBH). All reader settings were kept consistent throughout. Brightness 
was set at 128, sharpness at 184, white balance at 135, gamma at 128, exposure at 2384, and 
gain at 1, hue at 139 and saturation at 145. 
 
Analysis of results 
"
Results were standardised to spot forming cells (SFCs) per 106 cells. The mean and standard error 
of the triplicate wells was calculated using GraphPad Prism and presented on graphs.  In order to 
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assess the significance of peptide specific T cell responses detected, one tailed paired T-tests 
were carried out. p<0.05 was considered to be statistically significant[80].  
 
"
"
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Results 
 
IFN-γ ELISPOT assays are useful for assessing the frequency and functionality of antigen specific 
T cells in a sample. T cells specific for oncogenic HPV proteins E6 and E7 are expected to be at 
low frequency in the tumour and peripheral blood of patients, and it was therefore important to 
optimise an assay for the detection of these rare cells[59, 63, 75, 81]. For the purpose of 
optimisation, T cell responses of healthy HLA-A2 donors to EBV peptide CLG were investigated. 
This project focused on the optimisation of a cultured ELISPOT assay which would allow for 
detection of low frequency T cell responses which may not be detectable by standard ELISOPT 
assay. 
     
Standard ELISPOT assays can detect T cell responses to EBV peptide IED  
 
In order to demonstrate that a IFN-γ ELISPOT assay could be effectively utilised for the detection 
and quantification of T cell responses, a standard ELISPOT assay was carried out on PBMCs 
tested immediately ex vivo. Blood was taken from a healthy donor with known responses to the 
EBV peptide IED, and an ELIPSPOT assay was carried out following the manufacturer’s 
instructions. During this investigation the plates were blocked with 10%FBS in RPMI 1640, and 
1x105 cells were added to each well. The assay was carried out twice on different days, with cells 
tested in triplicate wells to determine the reproducibility of the assay. 
 
The well containing cells stimulated with PHA (positive control) well was fully saturated with spots 
which indicate that the cells used during this assay were healthy and functional. These wells could 
not be accurately read by the ELISPOT plate reader as there are so many spots that they 
overlapped and covered the entire well(#).The negative control wells, in which cells were 
stimulated with DMSO alone, showed no IFN-γ production which was indicated by a lack of spots 
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in these wells (figure 1c). Via paired T-test, the antigen specific response was shown to be 
statistically significant compared to the negative control in both repeats 1 and repeat 2.  p=0.003 
and 0.0007 respectively (figure 1a, 1b). Spot numbers were consistent both within internal 
replicates and also between the two experiments carried out on the same donor on different days. 
The negative control wells (DMSO) appeared clean and clear spots were visible in response to the 
IED peptide(figure 1c).  
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a.                                                                                                
 
 
            
 
 
b.              
 
 
                                      
 
 
 
 
 
 
 
c.             
  
 
 
          DMSO –ve control              IED response               PHA + control 
Figure 1. Standard ELISPOT assay carried out on PBMCs isolated from a healthy donor with a 
known response to EBV peptide IED. Plates were blocked with 10%FBS in RPMI 1640, and 1x105 
cells were added per well. Antigen specific responses to IED are shown, as well as negative and 
positive controls, in which cells were tested against DMSO and PHA respectively. # indicates the 
PHA well was fully saturated and therefore the number of spots cannot be determined accurately. 
Data shown as SFC/ 106 PBMCs (+standard error of the mean).  Paired T-test was performed 
***p<0.005 (a) Graph to show mean spot forming cells (SFC) per million repeat 1. (b) Graph to 
show mean spot forming cells (SFC) per million repeat 2 (c) Representative images of control and 
test wells. 
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Blocking with BSA results in a speckled appearance of the wells. 
 
This project focused on the development of a cultured ELISPOT for the amplification and detection 
of low frequency T cell responses to known antigens. Standard ‘ex vivo’ and cultured ELISPOT 
assays were carried out in parallel on PBMCs isolated from 2 HLA-A2 donors so that the effect of 
culturing the cells could be seen by direct comparison. In an attempt to standardise the assay and 
identify a suitable media to culture the cells in, PBMCs were cultured in AIM-V, Opti-Mem, 
10%FBS in RPMI 1640 or 10%autologous plasma in RPMI 1640 medium (3x106cells in 2ml) for 6 
days in the presence of CLG and were subsequently applied to a standard ELISPOT assay. 
Following the advice from a faculty member at the Institute of Cancer Sciences at the Birmingham 
University, 10% BSA in AIM-V was used to block the plates as this had been shown to produce 
consistent results in standard ex vivo ELISPOT assays in a clinical trial[82].  
 
Background on the cultured ELISPOT plates was so high it was not possible to draw conclusions 
from the data obtained (figure 2a,2b). When the wells were inspected visually, a speckled 
appearance was observed (figure 2d). The same speckled appearance of the wells was also seen 
in plates from the ‘ex vivo’ ELISPOT assay which had been conducted in parallel using the same 
blood sample (figure 2c). No antigen specific responses could be detected above background in 
either assay blacked with BSA.  Clearly it was not possible to draw firm conclusions on optimal 
culture conditions from this investigation, but this batch of BSA was disregarded as a potential 
blocking reagent for subsequent investigations. 
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a.                  b. 
 
 
      
 
             
 
  c. 
 
 
 
 
                
 
 
 
 d. 
 
 
 
       DMSO -ve control       CLG response          PHA +ve control 
 
Figure 2. Cultured and ‘ex vivo’ ELISPOT assays carried out on PBMCs isolated from 2 HLA-A2 
positive healthy donors. For cultured assays, PBMCs were cultured for 6 days with CLG peptide in 
AIM-V, Opti-mem, 10%FBS in RPMI 1640 (FBS) or 10% autologous plasma in RPMI 1640 (autol).  
Plates were blocked with 10% BSA in AIM-V medium. Antigen specific responses to CLG peptide, 
as well as negative controls in which cells were supplemented with DMSO alone are shown. PHA 
positive control wells were fully saturated with spots in all cases (data not shown) Data shown as 
SFC/ 106 PBMCs (+standard error of the mean).  Paired T-test was performed *p<0.05 (a) Donor 2 
cultured ELISPOT. (b). Donor 4 cultured ELISPOT (c) Donors 2 and 4 ‘ex vivo’ ELISPOT assays 
(d) Representative images of wells from cultured ELISPOT assay. 
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Blocking with autologous plasma reduces background 
 
Due to high backgrounds resulting from blocking the ELISPOT plates with BSA, the blocking 
reagent was changed to 10% autologous plasma in RPMI 1640. Autologous plasma may be a 
good alternative to FBS because it is less likely to contain foreign antigens that could lead to high 
backgrounds.  Standard ‘ex vivo’ and cultured ELISPOT assays were again carried out in parallel 
on PBMCs isolated from 2 HLA-A2 donors so that the effect of culturing the cells could be seen by 
direct comparison. In an attempt to identify a suitable media to culture the cells in, PBMCs were 
once more cultured in AIM-V, Opti-Mem, 10%FBS in RPMI 1640 or 10%autologous plasma in 
RPMI 1640 medium (3x106cells in 2ml) for 6 days in the presence of CLG and were subsequently 
applied to a standard ELISPOT assay. 
 
The plates from both the ‘ex vivo´ and cultured ELISPOT assays appeared much cleaner than the 
plates in the previous experiment which had been blocked with BSA, and background readings 
were reduced (figure 3a-e). In cultured ELISPOT assays very little difference was seen between 
the negative control and the antigen specific response. However, a statistically significant 
difference was seen between antigen specific and background when PBMCs from donor 5 were 
cultured in 10%FBS in RPMI 1640 and the plate was blocked with 10%autologous plasma 
(p=0.027) (figure 3 a, 3b). A smaller CLG specific response was also detected when PBMCs from 
the same donor were cultured in RPMI supplemented with 10% autologous plasma. Background in 
the ‘ex vivo’ assays was low and antigen specific responses could be detected. Donor 5 showed a 
statistically significant antigen specific T cell response compared to the negative control (p=0.027). 
results suggest that culturing in RPMI supplemented with 10% FBS may be optimal based on 
results from 1 donor but tends to give high backgrounds in cultured ELISPOT assays, and 
therefore some antigen specific response may not be detected above background levels. Donor 3 
is expected to respond to CLG, however a significant response is not seen ex vivo and culturing 
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does not amplify it. Donor 5 has a significant CLG response ex vivo which is increased after 
culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57"
"
a.                                                                         b. 
 
                          
                                                           
 
 
 
 
c.                                                                     
 
 
 
 
 
 
 
 
 
d. 
 
 
DMSO –ve control                CLG response                   PHA +ve control 
 
Figure 3. Cultured and ‘ex vivo’ ELISPOT assays carried out on PBMCs isolated from 2 HLA-A2 
positive healthy donors. For cultured assays, PBMCs were cultured for 6 days with CLG peptide in 
AIM-V, Opti-mem, 10%FBS in RPMI 1640 (FBS) or 10% autologous plasma in RPMI 1640 (autol).  
Plates were blocked with 10% autologous plasma in RPMI 1640. Antigen specific responses to 
CLG peptide, as well as negative controls in which cells were supplemented with DMSO alone are 
shown. All PHA positive control wells were fully saturated with spots (not shown) . Data shown as 
SFC/ 106 PBMCs (+standard error of the mean).  Paired T-test was performed *p<0.05 (a) Donor 3 
cultured ELISPOT. (b). Donor 5 cultured ELISPOT (c) Donors 3 and 5 ‘ex vivo’ ELISPOT assays 
(d) Representative images of wells from cultured ELISPOT assay. 
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A significant antigen specific response is seen when cells are cultured in AIM-V.  
 
Due to inconclusive results from previous experiments, and upon further inspection of the literature 
and advice from colleagues, we decided to focus on culturing cells in serum free AIM-V medium or 
RPMI 1640 supplemented with 10% autologous plasma. Standard ‘ex vivo’ and cultured ELISPOT 
assays were carried out in parallel on PBMCs isolated from 1 HLA-A2 donor. PBMCs were isolated 
and cultured for 6 days with CLG peptide (3million cells in 2ml). In an attempt to reduce 
background which may occur if stimulated cells were already producing IFN-γ when they were 
applied to the ELISPOT assay, half of the cells were washed on day 5 to remove the peptide and 
left to rest overnight in their appropriate medium. On day 6 the cells were applied to a standard 
ELISPOT assay at 1x105 cells per well. Plates were blocked with 10%FBS in RPMI 1640 or 10% 
autologous plasma in RPMI 1640. A new batch of BSA was also retested as a blocking agent. 
PBMCs were also isolated from a second donor and the for the sake of time efficiency, the effects 
of altering the blocking reagent used were tested by standard ‘ex vivo´ELISPOT assay.  
 
When the PBMCs were cultured in autologous plasma overall spot numbers are low, but 
background levels are relatively high, with no significant CLG-specific response detected with any 
blocking reagent (figure 4a). When cells were cultured in AIM-V medium, antigen specific 
responses were clearly visible when using some blocking agents. A statistically significant CLG-
specific response was seen in wells blocked with BSA (p=0.04) and autologous plasma (p=0.007) 
(figure 4b). When cells which had been cultured in AIM-V were applied to wells blocked with FBS, 
background was very high and the wells appeared speckled (figure 4c). Washing and resting the 
cells before conducting the cultured ELISPOT assays did not reduce background relative to the 
antigen specific response (figure 4a,4b). The new batch of BSA did not elicit the same speckled 
appearance of the wells and significant antigen specific responses were detected when cells were 
cultured in AIM-V medium. Due to concerns that autologous plasma may not always be available 
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and would therefore make an unsuitable blocking reagent, subsequent cultures were set up in AIM-
V and plates were blocked with BSA. 
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a.                                                                             b. 
 
 
 
 
 
                         
 
          c. 
                                                       
 
 
 
 
 
 
                 d. 
 
 
 
                      DMSO –ve control          CLG response           PHA +ve control 
 
Figure 4. Cultured and ‘ex vivo’ ELISPOT assays carried out on PBMCs from 1 healthy donor 
known to have a detectable response to CLG. Plates were blocked with 10%FBS in RPMI 1640, 
10% autologous plasma in RPMI 1640 (autol) or 10% BSA in AIM-V. 1x105 cells were added per 
well. Antigen specific responses to CLG peptide, as well as negative controls in which cells were 
tested with DMSO are shown. PHA positive control wells were fully saturated with spots (not 
shown) Data shown as SFC/ 106 PBMCs (+standard error of the mean).  Paired T-test was 
performed *p<0.05, **p<0.01 (a) PBMCs cultured in RPMI 1640 supplemented with 10% 
autologous plasma. (b) PBMCs cultured in AIM-V medium. (c)’ex vivo’ ELISPOT assays carried 
out on two donors tested with each of the 3 blocking reagents  (d) Representative images of wells 
blocked with 10%FBS in RPMI 1640 and cells cultured in AIM-V were added  
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Culturing PBMCs significantly amplifies the antigen specific response 
 
In order to test whether culturing PBMCs in AIM-V  and blocking plates with 10% BSA produced 
consistently low negative control backgrounds, and to investigate whether culturing the cells with 
peptide significantly amplified the antigen specific response, ‘ex vivo’ and cultured ELISPOT 
assays were carried out in parallel on 5 HLA-A2 positive healthy donors. The mean number of 
spots in the negative control wells on the ELISPOT assay was subtracted from the corresponding 
peptide exposed wells. Donors 1 and 3 were tested twice to examine the reproducibility of the data.  
 
Throughout this investigation, the PHA positive control wells were fully saturated with spots. All 
donors showed an increase in spot number after culture. This increase was statistically significant 
in assays carried out on PBMCs from donor 3 (p=0.04) and donor 5 (p=0.02), and approached 
significance in the assay on PBMCs from donor 4 (p=0.054). Repeat assays which tested T cell 
responses from Donor 1 results closely matched with little variability indicating that the result was 
reliable. In contrast, donor 3 showed huge variability between repeats. CLG specific response was 
not amplified during culture for one investigation on PBMCs isolated from donor 3. (figure 5).  
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Figure 5. Comparison of standard ‘ex vivo’ and cultured ELISPOT assays carried out in parallel on 
PBMCs isolated from 5 HLA-A2 positive healthy donors. PBMCs were cultured in AIM-V medium 
supplemented with CLG. All plates were blocked with 10% BSA and 1x105 cells were added per 
well. In all cases background was low and subtracted from the CLG response results. PHA positive 
control wells were fully saturated with spots (not shown) Data shown as mean spot forming cells 
(SFC) per million (+ standard error of the mean). Paired T tests were performed *p<0.05 
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Addition of IL-2 increases background 
 
In order to test whether adding IL-2 to the culture mix would significantly amplify the antigen 
specific response, cultured ELISPOT assays were carried out on 2 HLA-A2 positive healthy donors 
previously seen to have good CLG-specific responses. As previously described, PBMCs were 
cultured for 6 days in AIM-V supplemented with CLG (3x106cells in 2ml). On day 3 IL-2 was added 
to half of the cells in culture. Plates were blocked with 10% BSA in AIM-V. 
 
Addition of IL-2 to the culture mix increased the number of cells secreting IFN-γ. However, this 
increase was not restricted to CLG-specific responses. Negative control wells had dramatically 
higher spot numbers, and no significant antigen specific response was detected. (Indeed an 
antigen-specific response detected with donor 5 was lost when IL-2 was added to the culture). It 
was concluded that addition of IL-2 did not improve responses and should not be used in 
subsequent investigations. 
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Figure 6. ELISPOT assays carried out to investigate the effect of adding IL-2 to the culture mix. 
PBMCs isolated from HLA-A2 positive healthy donors. PBMCs were cultured in AIM-v medium 
supplemented with CLG. 20IU/ml IL-2 was added to half of the cells on day 3. All plates were 
blocked with 10% BSA and 1x105 cells were added per well. PHA positive control wells were fully 
saturated with spots (not shown) Data shown as SFC/ 106 PBMCs (+standard error of the mean).  
Paired T-test was performed *p<0.05 
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Culturing with HPV16 peptide pools for E6 and E7 reduced PHA response 
 
Before committing to an ELISPOT protocol for investigation of HPV 16 E6 and E7 responses from 
cancer patients, it was important to ensure that the optimised protocol for detection of EBV peptide 
responses was transferable and could be used in combination with commercially available 
pepmixes. Frozen aliquots of PBMCs from 7 healthy donors were selected at random. In parallel, 
standard ‘ex vivo’ and cultured ELISPOT assays were carried out. PBMCs were thawed and rested 
overnight to eliminate cells which has been damaged by the freezing/ thawing process. Cells were 
then applied to a standard ELISPOT, or cultured for 6 days in AIM-V supplemented with HPV16 
peptide pools (pepmixes) for oncogenic proteins E6 and E7 before the assay was conducted. To 
use less of the pepmixes and reduce costs, cells were cultured in a smaller volume of medium 
(1.5million cells in 1ml). 
 
 Antigen specific responses were not detected from any of the cone cells in either standard or 
cultured ELISPOT assays. Of course this could be a true result as it was not known whether the 
randomly selected donors carried HPV-specific T cells. However, it was noted that cultured cells 
showed dramatically reduced PHA responses. In all ‘ex vivo’ assays the PHA positive control wells 
were fully saturated with spots, whereas PHA wells from cultured cell experiments were much 
cleaner with relatively few spots(figure 7a,7b) 
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Figure 7. Standard ‘ex vivo’ and cultured ELISPOT assays carried out in parallel on PBMCs. 
PBMCs were cultured in AIM-V medium supplemented with HPV-16 E6 and E7 pepmixes. All 
plates were blocked with 10% BSA and 1x105 cells were added per well. In all cases background 
was low and subtracted from the CLG response results.  # indicates the PHA well was fully 
saturated.  (a) Data shown as SFC/ 106 PBMCs (+standard error of the mean).  Antigen specific 
responses and PHA positive controls are shown. (b)  Representative images from PHA positive 
control wells from standard ‘ex vivo´  and cultured ELISPOT assays. 
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Culturing cells in a reduced volume of medium may diminish their ability to produce IFN-γ 
 
In order to investigate whether cells had become reduced in their ability to produce IFN-γ due to 
the smaller culture volume or inhibitory effects of supplementing the cells with E6 and E7 peptide 
pools, standard ‘ex vivo’ and  cultured ELISPOT assays were set up in parallel on 2 donors 
previously seen to respond to EBV peptide CLG. PBMCs were isolated from donors 4 and 5. PHA 
positive and DMSO negative controls were run as well as test wells supplemented with either CLG 
alone, or CLG, E6 and E7 together in order to assess whether  addition of E6 and E7 immediately 
ex vivo inhibited T cells production of IFN-γ. PBMCs were also set up in culture in AIM-V 
supplemented with CLG at the concentration previously used, CLG at a lower concentration 
(comparable to the concentration of HPV peptides used) and CLG at this lower concentration with 
E6 and E7 peptide pools. 1.5x106 cells were cultured for 6 days in 1 ml of medium before a 
standard ELISPOT assay was carried out testing for CLG responses. 
 
Donors 4 and 5 both showed similar ‘ex vivo’   T cell responses to CLG as was seen in previous 
assays. Donor 4 and donor 5’s ‘ex vivo’ responses were ~150 and ~ 25 SFC/106 cells respectively 
in this and prior assays.  Addition of E6 and E7 premixes did not significantly impact antigen 
specific responses (figure 5, 8a,8b). PHA responses were high for both donors during the ‘ex vivo’ 
assays and the wells were saturated with spots (figure 8c). No antigen specific responses were 
seen after 6 days of culture with any of the peptide combinations (figure 8a,8b). Furthermore the 
PHA response was significantly reduced. PHA wells were not saturated with spots for any of the 
cultured ELISPOT assays suggesting the cells were not healthy or were functionally impaired 
(figure 8c).  
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Figure 8. Standard ‘ex vivo’ and cultured ELISPOT assays carried out in parallel on healthy donors 
with a known response to EBV peptide CLG. PBMCs were cultured in AIM-V medium 
supplemented with CLG at the same concentration previous experiments (CLGhigh), CLG at the 
same concentration as HPV pepmixes had been used (CLGlow), or CLG and HPV-16 E6 and E7 
pepmixes together. All plates were blocked with 10%BSA and 1x105 cells were added per well. In 
all cases background was low and subtracted from the CLG response results. Graph shows mean 
spot forming cells (SFC) per million. Antigen specific responses and corresponding PHA positive 
controls for each assay are shown. # indicates the PHA well was fully saturated (a) Donor 4 
standard and cultured ELISPOT (b) Donor 5 standard and cultured ELISPOT (c)  Representative 
images from PHA positive control wells from standard ‘ex vivo´  and cultured ELISPOT assays. 
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Discussion 
 
This project has clearly demonstrated the sensitivity of the cultured IFN-γ ELISPOT assay, and the 
importance of carefully considered variables such as culture conditions, blocking reagents and 
environmental changes which may drastically impact results. Multiple protocols have been 
described in the literature, and were adapted and tested during the course of this study[67, 71]. It 
was important to identify a protocol which would be broadly suitable for all donors and patients and 
to optimise a single protocol for both standard ‘ex vivo’ and cultured ELISPOT assays so that 
results of parallel experiments could be compared. In accordance with previously described data, 
we have shown that small variations in the protocol can make huge differences to the results 
obtained and thus leads to unreliable data [67, 83]. Harmonisation of the assay, which involves a 
process of development, optimisation and validation, was required before a chosen protocol was 
utilised for the investigation of patient samples[76]. This study has focused on the optimisation of a 
cultured ELISPOT assay which has been shown to be effective for amplification and detection of 
low frequency memory T cell responses[71, 73].  
 
Preliminary standard ELISPOT assays testing for IED responses, clearly demonstrated the 
proficiency of the ELISPOT assay. The negative control wells appeared clean and a significant 
antigen specific T cell response was detected. However, there was concern that FBS may not be 
broadly compatible for blocking plates as it may introduce variation such as batch disparity. It is 
also possible that foreign antigens in FBS may cause T cell activation in some donors or 
patients[78]. Cross-reactivity with detection antibodies was also a concern and for these reasons 
FBS was side-lined as a potential blocking reagent[84].  
 
The significance of identifying a suitable blocking reagent was highlighted during the course of this 
project. Blocking with BSA was highly recommended by a colleague at the Institute of Cancer 
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Sciences, who had used this blocking reagent during clinical trials and achieved consistently low 
background results. However, we found that blocking with BSA in initial cultured and ‘ex vivo’ 
assays resulted in a speckled appearance of the wells which has not been previously reported. 
This appearance may have been due to contaminants in the BSA which could have caused non-
specific T cell activation in all wells. However, the speckles were distinctly different in size, shape 
and intensity from spots seen in other assays. It is possible that components of the BSA may have 
formed particulates which were detected in the wells. In order to confirm the reason for the 
speckled appearance of the wells, an assay could be carried out in which the plates were blocked 
with BSA, but no PBMCs were added to the reaction, thus any spots seen could be attributed to 
issues with the BSA and not to IFN-γ production by T cells. This batch of BSA was discarded and a 
new batch was subsequently tested with improved results. Autologous plasma was collected 
during PBMC isolation and tested for efficacy as a blocking reagent for the ELISPOT assay. It was 
expected that plasma isolated from the donor being tested would make a good blocking reagent 
because donors would be unlikely to mount T cell responses to their own plasma and thus, 
compared to FBS, autologous plasma may make a good alternative. The use of this blocking 
reagent dramatically reduced background in both ex vivo and cultured ELISPOT assays compared 
to earlier experiments blocked with BSA. Blocking with autologous plasma yielded a particularly 
good spontaneous background: antigen specific response ratio when cells were cultured in AIM-V 
supplemented with CLG before being applied to the assay (figure 4b). This result should be 
validated with numerous repeats with PBMCs from several donors.  
 
The optimal culture medium was investigated as multiple culture conditions were described in the 
literature [67, 71, 72]. It was hypothesised that cells should be cultured in serum free medium to 
reduce background as supplementation with whole serum may result in undesired T cell activation 
during culture and subsequent responses detected may not be specific to the antigen of interest. 
We were concerned that the PBMCs would not survive and remain healthy after 6 days of culture 
in serum free medium. However, initial investigations did not indicate that changing the culture 
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medium resulted in significant differences in survival or functionality of the cultured cells and so 
only AIM-V medium(serum free) and RPMI 1640 supplemented with 10% autologous plasma were 
investigated further.  
 
Interestingly upon further inspection, when cells were cultured in RPMI 1640 supplemented with 
autologous plasma SFC per million PBMCs were low and no significant antigen specific response 
was detected.  In contrast, when cells from the same donor were cultured in serum-free AIM-V 
medium significant antigen specific responses were seen in plates blocked with autologous plasma 
or BSA (a new batch). Although the response detected in plates blocked with autologous plasma 
was greater than the response seen in wells blocked with BSA, BSA was used for all subsequent 
investigations as autologous plasma was not available for all samples tested during this project. 
For example, when screening for responses to HPV peptides we decided to use frozen stocks of 
PBMCs from consenting anonymised donors, as this avoided potential ethical issues that might 
occur with blood from laboratory colleagues. However autologous plasma was not available for 
these anonymised donors. Additionally, BSA was considered to be the preferred blocking reagent 
for use on patient samples as tumour samples may not always come with matching peripheral 
blood samples and so again autologous plasma may not be available. As previously mentioned 
absolute consistency is essential for reproducible ELISPOT data. My preliminary data suggest 
blocking with autologous plasma may be a good means to detect weak antigen specific responses 
in the ELISPOT assay and so in situations where such plasma is available it may well be worth 
further testing to see if this is the best approach to use. However, there is still the concern that 
autologous plasma will be different for every donor, and in some cancer patients may contain some 
immune suppressive components, which introduces another variable into the assay; in contrast, 
blocking with BSA offers a standardised reagent.  
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In accordance with previous studies, we have demonstrated that culturing the cells with peptide 
before the assay successfully amplifies the T cell response detected by the ELISPOT assay[71, 
73, 85]. This optimised protocol developed for the detection of CLG responses in healthy donors 
should be retested on multiple donors to ensure reproducibility. During this investigation, we 
cultured PBMCs for 6 days before they were applied to the ELISPOT assay on the advice of a 
colleague at the Institute of Cancer Sciences at the University of Birmingham. This varies from 
culture periods described in the literature. Some studies have suggested that 24 hour incubation 
with peptide may be sufficient to activate T cells in the sample sufficiently for detection without 
significantly increasing background [67]. Several other studies have suggested a longer incubation 
of 10 days including supplementation with IL-2 (which causes proliferation of T cells) is optimal to 
maximise T cell expansion[71]. We have found that culturing the cells before completing the 
ELISPOT assay results in increased spontaneous T cell activation and higher background levels 
compared to ex vivo’ assays. This is particularly evident in cultures that were set up supplemented 
with IL-2 where non-specific T cell amplification was such that no antigen specific responses could 
be detected above background levels. Further culturing conditions should be investigated for the 
optimisation of T cell expansion for future cultured ELISPOT assays. IL-7 and IL-15 are also 
implicated in inducing T cell proliferation and may be useful for maximising T cell expansion during 
the culture phase. [74] 
 
In the timescale of this project it was not possible to successfully translate the optimised cultured 
ELISPOT protocol, which had been effective in detecting of T cell responses to CLG, for the 
detection of T cell responses to HPV proteins E6 and E7. Initial ELISPOT assays did not detect T 
cell responses to E6 or E7 in PBMCs from any of the randomly selected donors. It is estimated that 
only ~23% of the population are infected with high risk HPV (1,6,16 or 18) and only a small 
proportion of these will be HPV-16[86]. It is therefore possible that the results we obtained from our 
investigation were real and the donors did not have E6 or E7-specific T cell responses. 
Alternatively pepmixes were not functioning properly to activate T cells to produce IFN-γ. This may 
73"
"
be because the pepmixes were added at too low a concentration to elicit a response, although 
EBV pepmixes were successfully used at a matching concentration during a clinical trial at the 
Institute of Cancer Sciences[82]. The major difference between the protocol used for these assays 
and my previous assays was the reduced volume of medium in which the cells were cultured. In 
previous assays 3 million cells were cultured for 6 days in 2ml AIM-V. In assays assessing T cell 
responses to E6 and E7, 1.5 million cells were cultured for 6 days in 1ml AIM-V, but were first 
incubated overnight in just 0.5ml of medium to allow the cells to encounter a higher concentration 
of peptide. It was surprising that there was dramatically reduced T cell activation seen in PHA wells 
after culture compared to cells that were tested immediately after thawing. In both ex vivo and 
cultured ELISPOT assays 1x105 cells were added per well and so differences cannot be accounted 
for by differing cell numbers between assays. Cells were inspected and counted under a 
microscope and appeared healthy after culture. Cells may have been alive when they were applied 
to the ELISPOT but have undergone apoptosis during the assay period[66]. Over stimulation of T 
cells may have caused the cells to lose function, although this is unlikely because only peptide-
specific T cells were stimulated during culture so only these cells would have become 
unresponsive[87] [88].  Other factors which may be responsible for these unexpected results 
include environmental changes such as problems with the thermostat of the incubator in which the 
cells were cultured, or potential issues with the PHA or culture medium although I ave no evidence 
for this (e.g. the same batches of PHA and culture medium were used for both ex vivo and cultured 
ELISPOT assays).  
In order to identify and rectify the issue causing unresponsiveness of the T cells in these final 
assays, the original, optimised, cultured ELISPOT assay should be repeated with another donor 
with a known response to CLG peptide as this will suggest whether the issue stems from problems 
with the reagents. Next, the culture process should again be scaled down so that again, 1.5 million 
cells are cultured in AIM-V supplemented with CLG at the concentration originally used. This will 
elucidate whether the problem is associated with the cells being cultured in a small volume of 
medium. If at this stage the assay is successful and PHA responses are strong and CLG specific 
74"
"
responses are amplified, then the reduced response seen here is likely to be attributed to transient 
environmental changes which may have occurred in the laboratory.  
 
ELISPOT assays have been shown to be a very effective method of detection and quantification of 
T cell responses [65] [22]. Here we have demonstrated the sensitivity of the assay and the scope 
of the cultured ELISPOT assay for the detection of low frequency T cell responses. We had 
intended to investigate T cell responses in patients with HPV+ oropharyngeal head and neck 
cancer. However, due to delays in receiving ethical approval it was not possible to analyse these 
responses. Future work must now focus on the transition of the optimised cultured ELISPOT assay 
described in this project into use for the detection of HPV-specific T cells in the tumours and 
peripheral blood of patients with head and neck cancer. Uncovering these responses may prove 
significant for the development of novel immunotherapy and vaccine strategies to combat this life 
threatening cancer.  
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